iNtRON Biotechnology Inc Total Liabilities
iNtRON Biotechnology Inc total liabilities. Based on the latest financial reports, iNtRON Biotechnology Inc (048530) has total liabilities worth ₩4.73 Billion KRW (≈ $3.20 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of iNtRON Biotechnology Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of iNtRON Biotechnology Inc (2012–2024)
Total liabilities of iNtRON Biotechnology Inc from 2012 to 2024. This chart illustrates how iNtRON Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore 048530 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
iNtRON Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of iNtRON Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ARRAS MINERALS CORP.
F:9RJ
|
Germany | €914.00K |
|
AurosTechnology Inc.
KQ:322310
|
Korea | ₩58.38 Billion |
|
Seouleaguer Co. Ltd
KQ:043710
|
Korea | ₩71.04 Billion |
|
Travelzoo
NASDAQ:TZOO
|
USA | $54.09 Million |
|
ActRO Co. Ltd
KQ:290740
|
Korea | ₩55.33 Billion |
|
N. B. I. Industrial Finance Company Limited
NSE:NBIFIN
|
India | Rs874.88 Million |
|
Opter AB
ST:OPTER
|
Sweden | Skr13.27 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down iNtRON Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see iNtRON Biotechnology Inc assets under control.
Liquidity & Leverage Metrics
iNtRON Biotechnology Inc Total Liabilities Ratios Explained
iNtRON Biotechnology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how iNtRON Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for iNtRON Biotechnology Inc (2012–2024)
The table below shows the annual total liabilities of iNtRON Biotechnology Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩2.60 Billion ≈ $1.76 Million |
+38.37% |
| 2023-12-31 | ₩1.88 Billion ≈ $1.27 Million |
-94.59% |
| 2022-12-31 | ₩34.78 Billion ≈ $23.57 Million |
-33.14% |
| 2021-12-31 | ₩52.02 Billion ≈ $35.25 Million |
+243.19% |
| 2020-12-31 | ₩15.16 Billion ≈ $10.27 Million |
-37.03% |
| 2019-12-31 | ₩24.07 Billion ≈ $16.31 Million |
+53.26% |
| 2018-12-31 | ₩15.70 Billion ≈ $10.64 Million |
+2.07% |
| 2017-12-31 | ₩15.38 Billion ≈ $10.43 Million |
+47.13% |
| 2016-12-31 | ₩10.46 Billion ≈ $7.09 Million |
+76.39% |
| 2015-12-31 | ₩5.93 Billion ≈ $4.02 Million |
-23.17% |
| 2012-12-31 | ₩7.72 Billion ≈ $5.23 Million |
-- |
About iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.